These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35924413)

  • 1. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
    Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
    Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
    Masjedi M; Azadikhah S; Zand F; Asmarian N; Sabetian G; Ostovan M; Naderi-Boldaji V
    Acta Haematol; 2023; 146(2):137-143. PubMed ID: 36538914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study.
    Ferrandis R; Escontrela B; Ferrando C; Hernández M; Herrera J; Hidalgo F; Librero J; Llau JV; Martínez A; Pajares A; Tapia B; Arruti E; Bassas E; Blasi A; Calvo A;
    Rev Esp Anestesiol Reanim (Engl Ed); 2023 Mar; 70(3):129-139. PubMed ID: 36842685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
    Ribic C; Lim W; Cook D; Crowther M
    J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review.
    Kjaergaard AB; Fuglsang J; Hvas AM
    Semin Thromb Hemost; 2021 Oct; 47(7):824-842. PubMed ID: 34130342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
    Vahtera A; Vaara S; Pettilä V; Kuitunen A
    Thromb Res; 2016 Mar; 139():10-6. PubMed ID: 26916290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
    Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
    J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is monitoring of anti-factor Xa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?].
    Ding M; Ning Y; Song L; Li P; Xie F; Li S; Wang C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 May; 36(5):461-464. PubMed ID: 38845490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials.
    Bonfim LCMG; Guerini IS; Zambon MG; Pires GB; Silva ACF; Gobatto ALN; Lopes MA; Brosnahan SB
    J Crit Care; 2023 Oct; 77():154344. PubMed ID: 37244209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis.
    Hafiz A; Alkofide H; Al Sulaiman K; Joharji H; Aljohani S; Sarkhi KA; Alharbi R; Korayem GB; AlFaifi M; Alsohimi S; Aljuhani O
    Clin Appl Thromb Hemost; 2023; 29():10760296231191123. PubMed ID: 37547931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
    Eman A; Balaban O; Süner KÖ; Cırdı Y; Şahin F; Demir G; Pekşen Ö; Musmul A; Erdem AF
    Saudi Med J; 2022 Jul; 43(7):715-722. PubMed ID: 35830988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring anti-Xa Levels to Optimize Low-Molecular-Weight-Heparin Thromboprophylaxis in High-Risk Hospitalized Patients: A Stratified Meta-Analysis.
    John S; Wilkinson M; Ho KM
    Angiology; 2024 Mar; 75(3):249-266. PubMed ID: 36606749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.
    Ena J; Valls V
    Clin Exp Med; 2023 Aug; 23(4):1189-1196. PubMed ID: 36048371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
    Wang C; Ning YC; Song LP; Li PJ; Wang FH; Ding MX; Jiang L; Wang M; Pei QQ; Hu SM; Wang H
    BMJ Open; 2023 Oct; 13(10):e069742. PubMed ID: 37880168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis.
    Aggarwal MV; Jarrell AS; Gilmore VT; Aboagye JK; Haut ER; Hobson DB; Lau BD; Kickler T; Kraus PS; Shaffer DL; Shermock KM; Streiff MB; Zheng G; Kruer RM
    J Crit Care; 2019 Aug; 52():180-185. PubMed ID: 31078999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
    Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
    Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial.
    De Schryver N; Serck N; Eeckhoudt S; Laterre PF; Wittebole X; Gérard L
    J Crit Care; 2022 Aug; 70():154029. PubMed ID: 35381407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
    de Maat MMR; van Leeuwen HJ; Roovers L; Ahlers SJGM; Lambers J; Hovens MMC
    BMC Pharmacol Toxicol; 2024 Feb; 25(1):16. PubMed ID: 38321487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.